ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO776

FGF23 Is Associated With Cardiovascular Functional Capacity Before and After Kidney Transplantation

Session Information

Category: Transplantation

  • 2002 Transplantation: Clinical

Authors

  • Halim, Arvin, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Burney, Heather, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Li, Xiaochun, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Li, Yang, Indiana University School of Medicine, Indianapolis, Indiana, United States
  • Lu, Tzongshi, Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Hiemstra, Thomas, University of Cambridge, Cambridge, Cambridgeshire, United Kingdom
  • Zehnder, Daniel, North Cumbria Integrated Care NHS Foundation Trust, Whitehaven, Cumbria, United Kingdom
  • Lim, Kenneth, Indiana University School of Medicine, Indianapolis, Indiana, United States
Background

Impaired cardiovascular functional capacity is a major complication in CKD and associated with mortality. Fibroblast Growth Factor 23 (FGF23) is a bone-derived phosphaturic hormone that is involved in cardiac remodelling in CKD. To-date, it is unknown whether FGF23 has a role in regulating cardiovascular functional capacity in CKD. Herein, we sought to examine the relationship between FGF23 and exercise ventilatory response variables of cardiovascular functional capacity.

Methods

We analyzed a total of 235 patients from the Cardiopulmonary Exercise Testing in Renal Failure and After Kidney Transplantation (CAPER) cohort: 87 advanced chronic kidney disease (CKD) stage 5 patients who underwent kidney transplantation, 65 non-transplanted waitlisted CKD patients, and 83 hypertensive controls. 186 patients were followed longitudinally for 1-year. All patients underwent cardiopulmonary exercise testing (CPET).

Results

Patients in higher FGF23 quartiles had significantly lower mean arterial pressure (p<0.001) and lower BMI (p=0.004) compared to patients with lower levels of FGF23. There was no significant difference in sex (p=0.5) or age (p=0.08) across quartiles. Patients with high FGF23 levels exhibited impaired VO2Max (p<0.001) as well as VO2AT (p<0.001), peak exercise heart rate (p<0.001), max workload (p<0.001), and endurance time (p<0.001) compared to patients with low FGF23 levels. There was no significant difference in oxygen pulse (p=0.2). Patients in all quartiles achieved a mean respiratory exchange ratio ≥1.0. Among patients who underwent kidney transplantation, FGF23 significantly decreased at 2 months post-transplant (p<0.001), followed by significant improvement in VO2Max (p<0.001) and max workload (p<0.001) at 1-year. Multivariable regression modelling revealed significant association between FGF23 and VO2Max before and after kidney transplantation after adjusting for age, sex, systolic blood pressure, smoking status, dyslipidemia, and albumin and hemoglobin levels.

Conclusion

FGF23 levels are inversely associated with cardiovascular functional capacity before and after kidney transplantation. Our study suggests that FGF23 may be a regulator of alterations in cardiovascular functional capacity in CKD.

Funding

  • Other NIH Support